DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypercholesterolemia

Intervention: Rosuvastatin (Drug); Atorvastatin (Drug); Simvastatin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Joel Raichlen, Study Director, Affiliation: AstraZeneca
Russell Esterline, Study Director, Affiliation: AstraZeneca

Summary

The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.

Clinical Details

Official title: An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels.

Secondary outcome:

Percentage change in other cholesterol & triglyceride measures

Safety evaluation

To compare the efficacy of rosuvastatin with atorvastatin and simvastatin

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Discontinuation of all cholesterol lowing drugs, including dietary supplements.

- Documented history of, or high risk of coronary heart disease or other established

atherosclerotic disease. Exclusion Criteria:

- The use of lipid lowering drugs or dietary supplements after Visit 1.

- Active arterial disease eg Unstable angina, or recent arterial surgery

- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.

- Abnormal laboratory parameters as defined in the protocol.

Locations and Contacts

Additional Information

Starting date: November 2001
Last updated: March 13, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017